SK286523B6 - Použitie zmesi esenciálnych mastných kyselín obsahujúcej etylester kyseliny eikozapentaénovej a etylesteru kyseliny dokozahexaénovej na prípravu lieku na prevenciu úmrtia pacienta, ktorý prekonal infarkt myokardu - Google Patents

Použitie zmesi esenciálnych mastných kyselín obsahujúcej etylester kyseliny eikozapentaénovej a etylesteru kyseliny dokozahexaénovej na prípravu lieku na prevenciu úmrtia pacienta, ktorý prekonal infarkt myokardu Download PDF

Info

Publication number
SK286523B6
SK286523B6 SK1080-2001A SK10802001A SK286523B6 SK 286523 B6 SK286523 B6 SK 286523B6 SK 10802001 A SK10802001 A SK 10802001A SK 286523 B6 SK286523 B6 SK 286523B6
Authority
SK
Slovakia
Prior art keywords
ethyl ester
dha
epa
acid ethyl
medicament
Prior art date
Application number
SK1080-2001A
Other languages
English (en)
Slovak (sk)
Other versions
SK10802001A3 (sk
Inventor
Franco Pamparana
Original Assignee
Pharmacia Italia S. P. A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11381919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK286523(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia S. P. A. filed Critical Pharmacia Italia S. P. A.
Publication of SK10802001A3 publication Critical patent/SK10802001A3/sk
Publication of SK286523B6 publication Critical patent/SK286523B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK1080-2001A 1999-02-17 2000-02-07 Použitie zmesi esenciálnych mastných kyselín obsahujúcej etylester kyseliny eikozapentaénovej a etylesteru kyseliny dokozahexaénovej na prípravu lieku na prevenciu úmrtia pacienta, ktorý prekonal infarkt myokardu SK286523B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI000313A IT1308613B1 (it) 1999-02-17 1999-02-17 Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
PCT/EP2000/000957 WO2000048592A1 (en) 1999-02-17 2000-02-07 Essential fatty acids in the prevention of cardiovascular events

Publications (2)

Publication Number Publication Date
SK10802001A3 SK10802001A3 (sk) 2001-12-03
SK286523B6 true SK286523B6 (sk) 2008-12-05

Family

ID=11381919

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1080-2001A SK286523B6 (sk) 1999-02-17 2000-02-07 Použitie zmesi esenciálnych mastných kyselín obsahujúcej etylester kyseliny eikozapentaénovej a etylesteru kyseliny dokozahexaénovej na prípravu lieku na prevenciu úmrtia pacienta, ktorý prekonal infarkt myokardu

Country Status (26)

Country Link
US (2) US7462643B1 (cs)
EP (2) EP1152755B1 (cs)
JP (2) JP5441287B2 (cs)
KR (2) KR100823051B1 (cs)
CN (1) CN1230159C (cs)
AT (1) ATE216230T1 (cs)
AU (1) AU775078B2 (cs)
BR (1) BR0008153A (cs)
CA (1) CA2362271C (cs)
CZ (1) CZ301307B6 (cs)
DE (1) DE60000133C5 (cs)
DK (1) DK1152755T3 (cs)
EA (1) EA004312B1 (cs)
ES (1) ES2174814T3 (cs)
HK (1) HK1044720B (cs)
HU (1) HUP0200111A3 (cs)
ID (1) ID30205A (cs)
IL (2) IL144377A0 (cs)
IT (1) IT1308613B1 (cs)
NO (1) NO328797B1 (cs)
NZ (1) NZ513093A (cs)
PL (1) PL209078B1 (cs)
PT (1) PT1152755E (cs)
SK (1) SK286523B6 (cs)
WO (1) WO2000048592A1 (cs)
ZA (1) ZA200106029B (cs)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
ITMI20020269A1 (it) * 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
WO2003092673A1 (en) 2002-05-03 2003-11-13 Pronova Biocare As Use of epa and dha in secondary prevention
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
GB0210212D0 (en) * 2002-05-03 2002-06-12 Univ Southampton Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability
ITMI20022511A1 (it) * 2002-11-26 2004-05-27 Victorix Assets Ltd Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale.
GB2438566A (en) 2005-03-11 2007-11-28 Recon Oil Ind Private Ltd A synergistically heat stable oil media having eicosa pentaenoic acid (EPA) and docosa hexaenoic acid (DHA)
JP5134916B2 (ja) * 2005-07-08 2013-01-30 持田製薬株式会社 心血管イベント発症予防用組成物
EP1790339B1 (en) 2005-07-08 2014-06-04 Mochida Pharmaceutical Co., Ltd. Composition for prevention of occurrence of cardiovascular event
ES2277557B1 (es) 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
RU2437583C2 (ru) * 2005-12-21 2011-12-27 Бруди Текнолоджи, С.Л. Применение дгк (dha), эпк (epa) или эпк, полученных из дгк, для лечения патологии, связанной с окислительным повреждением клетки, a также их нетерапевтические применения
US7498359B2 (en) 2006-02-07 2009-03-03 Mochida Pharmaceutical., Ltd. Composition and method for preventing recurrence of stroke
WO2007142118A1 (ja) * 2006-05-31 2007-12-13 Mochida Pharmaceutical Co., Ltd. 多重リスク患者の心血管イベント発症予防用組成物
US20090264520A1 (en) * 2008-04-21 2009-10-22 Asha Lipid Sciences, Inc. Lipid-containing compositions and methods of use thereof
AU2009278317B2 (en) 2008-08-07 2014-12-18 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Long-term treatment of symptomatic heart failure
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
US20110144667A1 (en) * 2009-09-08 2011-06-16 Anthony Richard Horton Hernia patch
EP2519332B1 (en) 2009-12-30 2014-03-05 BASF Pharma (Callanish) Limited Simulated moving bed chromatographic separation process for the purification of polyunsaturated fatty acids
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
KR101681907B1 (ko) * 2012-02-27 2016-12-12 주식회사 케어사이드 혈액 순환 촉진 및 피부 질환 개선용 조성물
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
AU2013240427B2 (en) 2012-03-30 2017-08-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
EP3756658A1 (en) * 2012-09-24 2020-12-30 Aker Biomarine Antarctic As Omega -3 compositions
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
EP2883860B1 (fr) 2013-12-11 2016-08-24 Novasep Process Procédé chromatographique de production d'acides gras polyinsaturés
WO2015104464A1 (fr) 2014-01-07 2015-07-16 Novasep Process Procédé de purification d'acides aminés aromatiques
PL237374B1 (pl) * 2017-11-10 2021-04-06 Lambdafin Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego oraz jej zastosowanie

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034156A (ja) * 1983-08-08 1985-02-21 Hayashibara Biochem Lab Inc エイコサペンタエン酸包接化合物及びこれを含有した飲食物
US4526902A (en) * 1983-10-24 1985-07-02 Century Laboratories, Inc. Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions
NO157302C (no) 1985-12-19 1988-02-24 Norsk Hydro As Fremgangsmaate for fremstilling av et fiskeoljekonsentrat.
US4920098A (en) 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
IT1205043B (it) 1987-05-28 1989-03-10 Innova Di Ridolfi Flora & C S Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri
GB2218984B (en) 1988-05-27 1992-09-23 Renafield Limited Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US5059622A (en) * 1989-08-29 1991-10-22 Biosyn, Inc. Method for reducing blood pressure levels in hypertensive persons
JP2893866B2 (ja) 1990-05-25 1999-05-24 日本油脂株式会社 抗不整脈薬
US5324323A (en) 1992-09-09 1994-06-28 Telectronics Pacing Systems, Inc. Multiple channel cardiosynchronous myoplasty apparatus
US5208236A (en) 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
HUT71557A (en) 1992-12-11 1995-12-28 Ciba Geigy Ag Substituted benzazepinones, process for producing them and pharmaceutical compositions containing them
CN1082909A (zh) * 1993-01-03 1994-03-02 潘玉珍 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂
JPH07118229A (ja) 1993-10-19 1995-05-09 Fujisawa Pharmaceut Co Ltd 尿素誘導体およびその製造法
US5760081A (en) * 1994-05-10 1998-06-02 The General Hospital Corporation Omega 3 fatty acids in the prevention of ventricular fibrillation
JPH0812581A (ja) 1994-06-30 1996-01-16 Fujirebio Inc 虚血性心疾患治療剤
IT1274734B (it) 1994-08-25 1997-07-24 Prospa Bv Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti
MY118354A (en) 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
IT1277953B1 (it) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
US6333447B1 (en) 1996-03-29 2001-12-25 The General Hospital Corporation Transgenic model of heart failure
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
EA199900261A1 (ru) 1996-09-05 1999-10-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Генная терапия застойной сердечной недостаточности
US6313167B1 (en) 1997-06-16 2001-11-06 Nippon Suisan Kaisha Ltd. Composition having capability of removing risk factor during exercise
IT1308613B1 (it) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
EP1130027A1 (de) 2000-02-29 2001-09-05 Aventis Pharma Deutschland GmbH Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben

Also Published As

Publication number Publication date
EP1247523A1 (en) 2002-10-09
DE60000133T2 (de) 2002-11-21
AU2907500A (en) 2000-09-04
DE60000133C5 (de) 2014-02-27
ES2174814T3 (es) 2002-11-16
WO2000048592A1 (en) 2000-08-24
DK1152755T3 (da) 2002-07-22
KR100823051B1 (ko) 2008-04-18
EP1152755B1 (en) 2002-04-17
PL209078B1 (pl) 2011-07-29
EP1152755A1 (en) 2001-11-14
EA004312B1 (ru) 2004-02-26
PL350851A1 (en) 2003-02-10
KR20010102183A (ko) 2001-11-15
SK10802001A3 (sk) 2001-12-03
ID30205A (id) 2001-11-15
HUP0200111A3 (en) 2003-03-28
JP2010116414A (ja) 2010-05-27
CA2362271A1 (en) 2000-08-24
ZA200106029B (en) 2002-09-25
DE60000133D1 (de) 2002-05-23
IL144377A0 (en) 2002-05-23
US20090018193A1 (en) 2009-01-15
JP5441287B2 (ja) 2014-03-12
ITMI990313A1 (it) 2000-08-17
CN1343120A (zh) 2002-04-03
EA200100895A1 (ru) 2002-02-28
JP2002537252A (ja) 2002-11-05
PT1152755E (pt) 2002-09-30
CA2362271C (en) 2008-07-15
IT1308613B1 (it) 2002-01-09
BR0008153A (pt) 2001-11-06
CZ301307B6 (cs) 2010-01-06
NZ513093A (en) 2003-02-28
HK1044720B (zh) 2006-08-18
HUP0200111A2 (hu) 2002-05-29
ATE216230T1 (de) 2002-05-15
AU775078B2 (en) 2004-07-15
NO328797B1 (no) 2010-05-18
CN1230159C (zh) 2005-12-07
US7462643B1 (en) 2008-12-09
KR20070098954A (ko) 2007-10-05
NO20013938D0 (no) 2001-08-14
IL144377A (en) 2006-12-10
NO20013938L (no) 2001-08-14
CZ20012947A3 (cs) 2002-04-17
HK1044720A1 (en) 2002-11-01

Similar Documents

Publication Publication Date Title
SK286523B6 (sk) Použitie zmesi esenciálnych mastných kyselín obsahujúcej etylester kyseliny eikozapentaénovej a etylesteru kyseliny dokozahexaénovej na prípravu lieku na prevenciu úmrtia pacienta, ktorý prekonal infarkt myokardu
KR101336756B1 (ko) 뇌졸중 재발 예방용 조성물
JP5087280B2 (ja) 中枢神経系障害の治療のための、選択されたｎ−３系脂肪酸の高度濃縮組成物の使用
JP2006519244A (ja) 糖尿病患者の治療におけるω−３−脂肪酸の使用
AU2019204443B2 (en) Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
KR20080024511A (ko) 심혈관 이벤트 발병 예방용 조성물
US8114906B2 (en) Essential fatty acids in the treatment and/or inhibition of depression in patients with coronary heart or artery disease
AU2005244483B2 (en) Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease
JP2007532605A5 (cs)
MXPA01008213A (en) Essential fatty acids in the prevention of cardiovascular events

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20200207